Extranodal NK/T cell lymphoma (ENKL) is a rare subtype of lymphoma that shows a poor clinical outcome. The most common sites are the nasal cavity, nasopharynx, paranasal sinuses, tonsils and larynx. Because of P-glycoprotein expression on ENKL cells, ENKL is resistant to anthracycline-based chemotherapy. L-asparaginase-based chemotherapy with or without radiotherapy shows promising outcomes for advanced ENKL, but has limited efficacy in relapsed/refractory ENKL. immune-checkpoint inhibitors, histone deacetylase inhibitors, and monoclonal antibodies are being investigated. In this review, we summarize the new treatments for ENKL.
CITATION STYLE
Yi, W., Yang, T., Lin, S., Hao, R., Yu, J., Wang, Y., & Tong, X. (2022). New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma. Cancer Management and Research. Dove Medical Press Ltd. https://doi.org/10.2147/CMAR.S328846
Mendeley helps you to discover research relevant for your work.